Statins and Glucose Metabolism: An Endocrinology Perspective

Slides:



Advertisements
Similar presentations
Atorvastatin Calcium Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of.
Advertisements

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Statin Myopathy (AHA/ACC/NHLBI)
The Latest Lipid Guidelines:
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Statin Selection in the Elderly
Optimizing Statin Therapy
An Endocrinology Clinic in Dyslipidemia
Statin Selection Aimed to Reduce New-Onset DM Risk:
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Tailoring Statin Therapy in Women
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Does One Size Fit All in Obesity Management?
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Statins and the Elderly Patient
SGLT2 Inhibitors in the Modern Era: Why and Where?
Organizational Culture in the Oncology Medical Home
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Understanding Statin Metabolism
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes hazard rates by number of visits with reported statin use.
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.
Growing Diabetes Pandemic Worldwide
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Statins and HIV:.
Exploring Statin Intolerance
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Learning Objectives Metabolic Abnormalities Associated With T2D.
Lipid Clinic Challenge
Hyperkalemia in the Hospital
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Statins, Obesity, and Hyperlipidemia
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Glucose Management and Statin Therapy
The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
New Lipid-Lowering Guidelines
Glucose Management and Statin Therapy
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Statin Therapy in Patients With Insulin Resistance
PCSK9 Inhibitors and Real-World Evidence
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Statins and Glucose Metabolism: An Endocrinology Perspective

Goals

Common Knowledge

Benefits Statins Outweigh the Risks

Pitavastatin Has a Neutral Effect on FBG Across the Dose Range

J-PREDICT -- Pitavastatin No Increased Risk of T2D

Pitavastatin: Head-to-Head Statin Trials

Risk for New-Onset Diabetes With Statins Increases With Age

Benefit of Statin With Lifestyle Changes

Patient Education -- Team Approach

How to Proceed With Your Patient

Mechanism of Action: HMG-CoA Reductase

J-PREDICT and Take-Home Points

Abbreviations

Abbreviations (cont)